GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results

Inclusion Criteria: 1. Male or female subjects greater than or equal to 18 years old； 2. Written informed consent obtained prior to any study-related procedure being performed; 3. Subjects with life expectancy ≥3 months; 4. Eastern Cooperative Oncology Group performance score 0 - 2; 5. Subjects must have histologically or cytologically confirmed advanced or metastatic solid tumor; 6. At least one measurable lesion based on RECIST version 1.1 . Exclusion Criteria: 1. History of other malignancies within 3 years before screening,unless radical non-melanoma skin cancer or basal cell carcinoma of the skin or carcinoma in the situ of the cervix; 2. Have central nervous system metastases; 3. Prior treatment with SHP2 inhibitor; 4. Have major surgery within 28 days prior to the first dose of GH21; 5. Left ventricular ejection fraction (LVEF) \<50 %; 6. Females who are pregnant or breastfeeding ; 7. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; 8. Conditions that the investigator considers inappropriate for participation in this clinical trial.